View in EDS HTML Full Text PDF Full Text

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.

Saved in:

Bibliographic Details
Title:	Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.
Authors:	Adasme, Melissa F.¹ (AUTHOR), Parisi, Daniele² (AUTHOR), Van Belle, Kristien³ (AUTHOR), Salentin, Sebastian¹ (AUTHOR), Haupt, V. Joachim^1,4 (AUTHOR), Jennings, Gary S.¹ (AUTHOR), Heinrich, Jörg-Christian¹ (AUTHOR), Herman, Jean^3,5,6 (AUTHOR), Sprangers, Ben^3,5,7 (AUTHOR), Louat, Thierry³ (AUTHOR), Moreau, Yves² (AUTHOR), Schroeder, Michael¹ (AUTHOR) michael.schroeder@tu-dresden.de
Source:	PLoS ONE. 5/27/2020, Vol. 15 Issue 5, p1-26. 26p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	19326203
DOI:	10.1371/journal.pone.0233089